Two common polymorphisms in the b 1 -adrenergic receptor gene, Ser49Gly and Arg389Gly, are associated with variable antihypertensive response to metoprolol. We sought to determine whether similar pharmacogenetic associations were present with the negative chronotropic response phenotype to metoprolol. Metoprolol was titrated in 54 untreated hypertensive patients to achieve blood pressure control. We found no association between either resting or exercise heart rate at baseline (untreated) or in response to metoprolol by codon 389 genotype. In contrast, when compared by codon 49 genotype, Ser49 homozygotes had significantly higher resting heart rates at baseline (untreated) than Gly49 carriers (82710 versus 74711 bpm, respectively, P ¼ 0.016). When corrected for plasma concentration, we found no difference in reduction in exercise heart rate in response to metoprolol between Ser49 homozygotes and Gly49 carriers (0.7570.11 versus 0.5770.17%/ng/ml, respectively, P ¼ 0.37). However, if one fails to account for plasma concentration, trends toward a significant difference in heart rate reduction are seen between Ser49 homozygotes and Gly49 carriers (31% reduction versus 25% reduction, P ¼ 0.05). Our data suggest that neither the b 1 -adrenergic receptor Arg389Gly, nor the Ser49Gly polymorphisms are associated with variable negative chronotropic response to metoprolol. In addition, our data highlight the importance of measuring metoprolol concentration in order to account for variable pharmacokinetics and avoid misinterpretation of the data.
Introduction
Two common polymorphisms exist in the b 1 -adrenergic receptor gene, ADRB1, Arg389Gly and Ser49Gly. In vitro mutagenesis studies suggest both of these polymorphisms have functional consequences. 1, 2 We have found Arg389 homozygotes to have a greater magnitude of antihypertensive response and to be more likely to be considered 'responders' (defined as a X10% reduction in day time diastolic blood pressure (DBP)) to metoprolol than Gly389 carriers. 3 Other investigators have found similar associations with Arg389Gly genotype and blood pressure response to b-blockers as well as with contractile response to dobutamine. [4] [5] [6] We have also shown significant associations between these polymorphisms and both initial tolerability and left ventricular remodeling responses to b-blockade in heart failure patients. 7, 8 The association between these polymorphisms and heart rate, or heart rate response to b-blockers is less clear in the literature, and the negative chronotropic effect of b-blockers is relevant, as this is the primary mechanism of benefit of bblockers in certain settings (e.g. arrhythmias, angina). Thus, the aim of the present study was to compare pharmacogenetic associations with metoprolol across various negative chronotropic phenotypes.
Results
Allele frequencies were 0.76 for Arg389 and 0.85 for Ser49. The 54 patients were made up of 29 (54%) Arg389 homozygotes, 24 (44%) Gly389 heterozygotes, 1 (2%) Gly389 homozygote, 38 (70%) Ser49 homozygotes, 16 (30%) Gly49 heterozygotes, and no Gly49 homozygotes. Genotype frequencies were in Hardy-Weinberg equilibrium. The mean age of the subjects was 4978 years and 61% were male. Patients were generally obese, with a mean body mass index of 30.575.1 kg/m 2 . Baseline demographic characteristics did not differ by codon 49 or 389 genotype with the exception of race/ethnicity (data not shown). The racial/ ethnic breakdown of the overall population was 41 Caucasian, 10 African American, and three Hispanic/Latino. More African American subjects were Gly389 carriers (15 Caucasian/eight African American/two Hispanic/Latino) than Arg389 homozygotes (26 Caucasian/two African American/ one Hispanic/Latino) (P ¼ 0.041), which is consistent with known racial differences in codon 389 allele frequencies 9 and the a priori rationale for including race as a covariate in all analyses (see Materials and methods). There were no racial differences in codon 49 allele frequencies.
Baseline (untreated) heart rate measurements by codon 49 genotype are shown in Table 1 . Ser49 homozygotes had significantly higher 24-h heart rate and resting heart rate at 1430. Baseline resting and exercise (untreated) heart rate measurements did not differ by codon 389 genotype (data not shown).
All genotype groups were titrated to equivalent twice daily metoprolol doses, 120765 mg in Ser49 homozygotes, 120768 mg in Gly49 carriers, 121766 mg in Arg389 homozygotes, and 124764 mg in Gly389 carriers. Of the 54 patients, 53 completed treatment phase treadmill exercise testing. One patient was unable to complete the testing due to elevated blood pressure on the test day. Neither resting, nor maximal exercise heart rate response to metoprolol differed by codon 389 genotype (data not shown), either when all subjects were considered, or when analyses were confined to Caucasian subjects.
b-Blocker-induced reduction in resting or exercise heart rate values, corrected for S-metoprolol concentration, did not differ by codon 49 genotype at 1030 or 1430 (Table 2) . To further elucidate whether there were pharmacodynamic differences in heart rate response to metoprolol by genotype, we plotted the negative chronotropic response-plasma concentration relationship, pooling the data in all patients at 1030 and 1430 (Figure 1 ). The g (slopes) did not differ between Ser49 homozygotes and Gly49 carriers (Ser49 homozygote g ¼ À0.06, Gly49 carrier g ¼ À0.08; P ¼ 0.71).
Given that many investigators conducting drug target pharmacogenetic studies do not control for plasma drug concentration, we also tested the association between negative chronotropic response by genotype, without correcting for plasma concentration. In this case, we found Ser49 homozygotes had a greater negative chronotropic response than Gly49 carriers (31% reduction versus 25% b-blocker drug target pharmacogenetics AL Beitelshees et al reduction, P ¼ 0.05). Such differences were not evident at 1430, even when uncorrected for plasma concentration (25% versus 23%, P ¼ 0.52). Results for codon 49 were also similar when conducted only in Caucasian subjects (data not shown).
Discussion
Consistent with most other reports in the literature, we found no association between resting or exercise heart rate and codon 389 genotype. [4] [5] [6] [9] [10] [11] Similarly consistent with other reports in the literature, we found no association between heart rate response to b-adrenergic receptor antagonists and codon 389 genotype. [4] [5] [6] 12 With regard to associations with codon 49, our results agree with Ranade et al. 11 and find a significant association between untreated resting heart rate and codon 49 genotype in hypertensive individuals. However, other investigators have failed to find this association. 7, 13, 14 One explanation for this inconsistency may be differences in populations studied (i.e. hypertensive subjects versus those undergoing dobutamine stress echocardiogram or with heart failure). A second explanation for these differences could be a type I error, based on the number of comparisons made in our study. Therefore, our results with resting heart rate and codon 49 genotype should be interpreted with caution.
Although untreated resting heart rate was different by codon 49 genotype, we found no differences in untreated exercise HR or the resting or exercise heart rate responses to metoprolol corrected for plasma drug concentration. Additionally, when analyzed by linear regression analysis, there was also no difference by genotype. Given that g (the slope) represents the quotient of Emax/EC50, this suggests a lack of relevant pharmacodynamic differences by genotype in the negative chronotropic response to metoprolol.
Interestingly, when these data were not corrected for drug exposure, there were trends toward differences in the exercise heart rate response at the time of approximate peak drug concentration. These data highlight the importance of inclusion of pharmacokinetic analysis in drug target pharmacogenetic studies, to insure that observed differences are not false associations that are being influenced by variable pharmacokinetics.
Pharmacogenetics has historically focused on drug-metabolizing enzymes where measurement of drug concentration is the norm. However, relatively few pharmacogenetic studies focused on drug targets include pharmacokinetics or drug exposure in their analysis. [15] [16] [17] [18] [19] This failure to account for pharmacokinetics occurs despite the fact that a large percentage of drugs have variability in their pharmacokinetics. Our data suggest that such an omission can be important, potentially leading to spurious associations or difficulty in interpreting data. Further, it is likely not sufficient to simply determine genotype of relevant drugmetabolizing enzymes. In this population, we had separately genotyped for polymorphisms in the CYP2D6 gene (which controls approximately 70-80% of metoprolol's metabolism). 20 We found that CYP2D6 genotypes and activity scores between codon 49 genotype groups were nearly identical (data not shown), indicating that CYP2D6 genotype data alone (without plasma concentration data) would not have allowed the appropriate degree of correction for drug exposure. This is not surprising given that there can be up to 30-fold range in S-metoprolol concentrations among CYP2D6-extensive metabolizers. 20 Hence, failure to have measured plasma drug concentrations in this study may have resulted in spurious findings.
The second issue our data raises is that a pharmacogenetic association with one phenotype (e.g. blood pressure) cannot be extrapolated across other phenotypes (e.g. heart rate), even when the same drug is being investigated in the same individuals. While we and others have previously shown ADRB1 codon 389 is significantly associated with antihypertensive and other responses to b-blockade [3] [4] [5] we found no such association with negative chronotropic response to metoprolol in the same patients. This lack of association with heart rate response has also been documented by others. [4] [5] [6] 12 We believe that this finding is explained by differences in mechanisms of metoprolol between phenotypes studied. For instance, the antihypertensive effects of metoprolol are thought to be largely due to reduction in b-receptormediated renin release, while the effects on heart rate are likely due to direct inhibition of myocardial b-receptors, particularly in the sino-atrial node.
In summary, our data suggest no association between ADRB1 genotype and heart rate response to metoprolol, a finding that may have been misinterpreted had metoprolol plasma concentrations not been measured. This highlights the importance of being able to control for drug concentration in drug target pharmacogenetic studies. Our data also highlight the fact that pharmacogenetic associations can vary across phenotypes, even when the same patients and drug are studied.
Materials and methods

Patients
The population studied has been described elsewhere and the pharmacogenetic association with the blood pressure response to metoprolol in the first 40 of these subjects has been previously reported. 3 Briefly, the study included hypertensive men and women between the ages of 35 and 65 years. Hypertension was defined as an untreated (for at least 2 weeks) DBP X95 and p115 mmHg after sitting at least 5 min on two clinic visits separated by at least 3 days.
Patients were excluded if they had concomitant conditions that were being treated with antihypertensive medications or had other conditions that would preclude b-blocker use. 21 All subjects provided written informed consent. The protocol was approved by the University of Florida Institutional Review Board. All study visits took place in the University of Florida General Clinical Research Center (GCRC).
Study protocol Baseline studies. All patients underwent a 2-week washout of all antihypertensive medications to determine eligibility. Once eligibility was determined, 24-h hemodynamic monitoring was conducted using an Accutracker DX (SunTech Medical Instruments Inc., Raleigh, NC, USA) or SpaceLabs 90207 oscillometric ambulatory blood pressure monitor (SpaceLabs Inc., Redmond, WA, USA) according to previously described methods. 3 Baseline treadmill studies were performed on a day subsequent to ambulatory hemodynamic monitoring. A graded treadmill protocol was designed in which patients gradually reached 85% of their maximal predicted exercise heart rate calculated as (0.85 Â (220Àpatient's age)). A 12-lead ECG (CASE s 15, Marquette Electronics Inc., Milwaukee, WI, USA) was placed to monitor heart rate and conduction during the treadmill exercise. Heart rate was recorded for each patient at rest (supine), after at least 5 min in the supine position. Treadmill exercise was then initiated at 3.3 mph with 0% incline. The speed remained constant for the duration of the exercise test, with the slope of the incline increased by 1% every minute up to the 7-min mark, if necessary. If patients did not reach target heart rate by 7 min, the slope was increased by 2% every minute beginning at the 8-min mark. Patients completed two treadmill studies on the same day, initiated at 1030 and 1430, respectively. These study times were chosen to approximately coincide with the expected maximum (C max ) and half-maximum ( Metoprolol therapy. Metoprolol therapy was initiated after baseline studies were completed. Patients took metoprolol tartrate 50 mg every 12 h (0830 and 2230) and were seen for weekly titration to 100 and 200 mg every 12 h if clinic DBP was greater than 90 mmHg and the patient did not experience intolerable side effects. Patients who achieved target DBP continued therapy for at least 4 more weeks and were seen biweekly for clinic blood pressure measurements. Those who failed to reach target BP on the maximum metoprolol dose, but had a DBP reduction X10% were also treated for 4 more weeks. Patients who failed to meet either of these response criteria proceeded to the end of study evaluation.
Treatment studies. Ambulatory hemodynamic monitoring and treadmill studies were repeated after at least 4 weeks of stable dose metoprolol. Subjects exercised using the same treadmill protocol (i.e., grade and duration) as baseline, and metoprolol-treated 24 h ambulatory heart rate, and resting and exercise heart rates at 1030 and 1430 were determined. In addition, subjects were admitted to the GCRC for a steady-state pharmacokinetic study. Indwelling venous catheters were placed, and blood samples were drawn immediately before, and at 2, 4, 8, and 12 h after the metoprolol dose for pharmacokinetic analysis. R-and Smetoprolol plasma concentrations were determined by chiral HPLC with fluorescence detection as previously described. 22 Genotyping Blood samples were obtained for genotyping at study entry. Genomic DNA was isolated from whole blood using a commercial kit (Purgene s , Gentra Systems, Minneapolis, MN, USA). Genotypes were determined by PCR and subsequent RFLP with Sau96I for codon 49 using protocols modified from previously described methods.
1,23 RFLP genotypes were scored by at least two blinded investigators who were unaware of the subjects' clinical drug responses. PCR followed by Pyrosequencing (PSQ HS 96A) was used for genotyping codon 389, with genotypes determined by Pyrosequencing software. Five samples were problematic and were sent for direct sequencing (Amersham, MegaBACE 1000) to ensure correct genotype assignment.
Statistical analysis
Resting and exercise heart rates were calculated as the average of 6 R-R intervals. In the case of exercise heart rate, this was based on the ECG recording in the minute after subjects achieved their target heart rate.
Because of the relatively infrequent occurrence of Gly49 homozygotes and Gly389 homozygotes, it was decided a priori to pool heterozygotes and variant homozygotes and classify them as Gly49 carriers and Gly389 carriers. Given the allele frequencies for the ADRB1 polymorphisms among the 54 patients studied, we had 80% power to detect at least a 7.4% difference in reduction in exercise heart rate between genotype groups.
Baseline characteristics were compared between genotypes using w 2 , Fisher's exact tests, or Student's unpaired ttest, as appropriate. To investigate pharmacodynamic relationships, S-metoprolol plasma concentration and exercise heart rate response to metoprolol at the two time points were plotted by genotype group (Arg389 or Ser49 homozygotes and Gly389 or Gly49 carriers). The concentrationresponse curves revealed little evidence of nonlinearity and so were modeled with a linear pharmacodynamic model, where E ¼ E max /EC 50 Â C, when concentration is much less than EC 50 . Simplified, this equation is E ¼ g Â C, where g ¼ slope and is the pharmacodynamic parameter of interest that was compared by genotype. Heart rate treatment effect by genotype group was then analyzed using the generalized linear model procedure with race as a covariate. Given the influence of plasma concentration on the heart rate response, the heart rate responses (percent change from baseline) were corrected for plasma concentration at the time of treadmill study prior to such analyses.
All statistical analyses were performed using SPSS (version 11.0, SPSS Inc., Chicago, IL, USA) or SAS (version 8, SAS Institute Inc., Cary, NC, USA). A P-value of less than 0.05 was considered statistically significant. insightful comments regarding the manuscript. This study was supported by NIH Grants HL64691, HL68834, and by the University of Florida GCRC Grant RR00082.
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